MEDICUS PHARMA LTD. Paid-in-Kind Interest
MEDICUS PHARMA LTD. (MDCX) reported Paid-in-Kind Interest of $480.59 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2026-08-12
- MEDICUS PHARMA LTD. paid-in-kind interest for the quarter ending 2026-06-30 was $101.34K.
- MEDICUS PHARMA LTD. paid-in-kind interest for the quarter ending 2026-03-31 was $379.25K.
- MEDICUS PHARMA LTD. paid-in-kind interest for the quarter ending 2025-12-31 was $339.38K.
- MEDICUS PHARMA LTD. paid-in-kind interest for the quarter ending 2025-09-30 was $89.68K, a 898.33% increase year-over-year.
- MEDICUS PHARMA LTD. paid-in-kind interest for fiscal 2025 was $429.06K, a 479.77% increase from fiscal 2024.
- MEDICUS PHARMA LTD. paid-in-kind interest for fiscal 2024 was $74.00K, a 87.35% decline from fiscal 2023.
- MEDICUS PHARMA LTD. paid-in-kind interest for fiscal 2023 was $584.82K.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $101.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $480.59K 10-Q · filed 2026-08-12 | $819.98K derived: sum of 3 quarters · filed 2026-08-12 | $909.65K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $379.25K 10-Q · filed 2026-05-14 | $718.63K derived: sum of 2 quarters · filed 2026-05-14 | $808.32K derived: sum of 3 quarters · filed 2026-05-14 | $808.32K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $339.38K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $429.06K derived: sum of 2 quarters · filed 2026-03-25 | $429.06K derived: sum of 3 quarters · filed 2026-08-12 | $429.06K 10-K · filed 2026-03-25 |
| 2025-09-30 | $89.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $89.68K derived: sum of 2 quarters · filed 2026-08-12 | $89.68K 10-Q · filed 2025-11-14 | $57.43K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | -$32.25K derived: sum of 3 quarters · filed 2026-08-12 | -$23.27K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | -$32.25K derived: sum of 2 quarters · filed 2026-05-14 | -$23.27K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$32.25K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$23.27K derived: sum of 2 quarters · filed 2026-03-25 | $74.00K 10-K · filed 2026-03-25 | |
| 2024-09-30 | $8.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $106.25K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $97.27K 10-Q · filed 2025-08-11 | |||
| 2023-12-31 | $584.82K 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |